Adverum Biotechnologies (ADVM) Misses Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for wet AMD, Reports Recent Business Progress and Second Quarter
August 10, 2020 4:00 PM EDT-- Continued robust treatment response from both high and low doses --
-- Long-term durability beyond 15 months from single IVT injection with zero rescue injections in Cohort 1 --
-- Well tolerated across all Cohorts; encouraging early safety data from Cohort 4 --
-- OPTIC enrollment complete; planning to start pivotal trial in wet AMD mid-2021 --
-- Company to host conference call and webcast with Key Opinion Leader Dr. Arshad Khanani today at 1:30 pm PT / 4:30 pm ET --
... More